Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System | Zendy

Sengwee Toh | Zendy; Marsha E. Reichman | Zendy; Monika Houstoun | Zendy; Mary Southworth | Zendy; Xiao Ding | Zendy; Adrian F. Hernandez | Zendy; Mark Levenson | Zendy; Lingling Li | Zendy; Carolyn McCloskey | Zendy; Azadeh Shoaibi | Zendy; Eileen Wu | Zendy; Gwen L. Zornberg | Zendy; Sean Hennessy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System

Author(s) -

Sengwee Toh,

Marsha E. Reichman,

Monika Houstoun,

Mary Southworth,

Xiao Ding,

Adrian F. Hernandez,

Mark Levenson,

Lingling Li,

Carolyn McCloskey,

Azadeh Shoaibi,

Eileen Wu,

Gwen L. Zornberg,

Sean Hennessy

Publication year - 2012

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/2013.jamainternmed.34

Subject(s) - aliskiren , angioedema , medicine , hazard ratio , incidence (geometry) , retrospective cohort study , cumulative incidence , renin–angiotensin system , cardiology , endocrinology , cohort , blood pressure , confidence interval , physics , optics

Although certain drugs that target the renin- angiotensin-aldosterone system are linked to an increased risk for angioedema, data on their absolute and comparative risks are limited. We assessed the risk for angioedema associated with the use of angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and the direct renin inhibitor aliskiren.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research